A team of researchers from Queen Mary University of London have reported the genetic events involved in the early development of bowel cancer in patients with inflammatory bowel disease (IBD).
Such knowledge may be able to be exploited to design simple diagnostic tests to stratify patients with IBD at high risk of developing cancer.
IBD more than doubles an individual’s lifetime risk of developing bowel cancer, and the risk increases significantly if they have suffered with IBD for a sustained period of time. With this in mind, the study published in Gut performed in collaboration with researchers from St Mark’s Hospital and the University of Oxford set out to understand the genetics of how colorectal cancer develops in people with IBD.
Lead researcher Professor Trevor Graham from Barts Cancer Institute at Queen Mary said: “Predicting who with IBD is going to go on to develop bowel cancer is a big unmet need. If we could do it accurately, it would allow us to target care to those who need it most, and spare low-risk individuals unnecessary worry. Here we have determined which genetic mutations tend to occur early in IBD-associated bowel cancer development. These mutations could form the basis
Article originally posted at